Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Capital Leases (2018)

Zevra Therapeutics' Capital Leases history spans 3 years, with the latest figure at $396000.0 for Q4 2018.

  • For Q4 2018, Capital Leases changed N/A year-over-year to $396000.0; the TTM value through Dec 2018 reached $396000.0, changed N/A, while the annual FY2018 figure was $396000.0, N/A changed from the prior year.
  • Capital Leases reached $396000.0 in Q4 2018 per ZVRA's latest filing, down from $451000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $515000.0 in Q1 2018 to a low of $3000.0 in Q3 2015.
  • Average Capital Leases over 3 years is $235750.0, with a median of $211000.0 recorded in 2014.